Home > About us > Company Introductions
Company Introductions

 About Ustar

Ustar Biotechnologies (Hangzhou) Ltd. is an innovative molecular diagnostic company funded by the private sector. It was founded in 2005 by scientists from the US with the express goal of commercializing cutting-edge molecular technologies for the point-of-care.

The company's main office and manufacturing facilities are located in Binjiang District, Hangzhou, China. The new 2,000 square meter facilities includes a 800 square meters 100K grade clean room area, with a designed production capacity of 20 million tests per year.  The facility is constructed and equipped with  state-of-the-art technology and is ISO9001:2008, ISO13485:2012+AC2012 certified. Ustar owns a number of proprietary technologies including instrument-free nucleic acid extraction, isothermal amplification and rapid DNA amplicon detection device which form two unique nucleic acid testing platforms: microbe detection and SNP/Mutation detection. The company developed a series of isothermal amplification testing kits based on the two platforms for clinical use as well as disease control. The customer benefits of these products include accuracy, ease-of-use, and low-cost, instrument-free, and cross-contamination proof testing.                                                                                                                          

The application outlook of Ustar molecular testing platforms is promising in both the clinical and industrial field. Clinicallyit can be used for rapid, convenient and low-cost pathogen and SNP/mutation detection as a "companion diagnostic" or microbe genotyping tool for personalized medicine; industrially it can be used within R&D and clinical studies for pharmaceutical agent development. So far Ustar Biotech has developed several isothermal amplification kits for pathogen detection and genotyping, including tuberculosis, sexual transmitted diseases and HBV genotyping. The NATeasy™ Isothermal Amplification TB Detection Kitis listed as an Innovative technology recommended by the WHO. Ustar has also entered collaborations with renowned non-government organizations such as PATH, MBGF in developing and evaluating new testing kits, and with a number of Chinese research and clinical institutions on a number of significant health careprojects.

Ustar's vision is to become a leading company in commercializing molecular diagnostic assays for point-of-care use and resource-limited settings, bridging the gap between the advances in science/technology and the populations who are in need.